Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Blesl, Andreas, Krones, Elisabeth, Pollheimer, Marion J., Haybaeck, Johannes, Wiesspeiner, Ulrike, Lipp, Rainer W., Kump, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803685/
https://www.ncbi.nlm.nih.gov/pubmed/29430237
http://dx.doi.org/10.1159/000484473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803685/
https://www.ncbi.nlm.nih.gov/pubmed/29430237
http://dx.doi.org/10.1159/000484473

Ejemplares similares